Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

GSK, Sino Biopharmaceutical partner to distribute hepatitis B drug bepirovirsen across China
Commercialization agreement, infectious disease, small molecule, RNA-based therapy - Read more

MacroGenics sells GMP manufacturing operations to Bora Pharmaceuticals for $122.5M upfront
Acquisition, manufacturing, biologics, antibody, oncology, CDMO - Read more

Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy STEM-PD, equity investment undisclosed
Acquisition, neurological, cell therapy, AI/ML, milestone payments, royalties - Read more

Nxera Pharma out-licenses GPCR program to NewCo, eligible for up to $275M in milestones plus royalties
Licensing deal, small molecule, drug discovery, milestone payments, equity investment, rare disease - Read more

Curacle, MabTics, Memento Medicines sign $1.08B dual-antibody MT-103 technology transfer deal, $8M upfront
Licensing deal, antibody, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Inhibrx Biosciences' INBRX-106 plus Keytruda (pembrolizumab) doubles response rate in Ph2 head and neck squamous cell carcinoma trial
Antibody, cancer, monoclonal antibody, head and neck squamous cell carcinoma, OX40 agonist, combination therapy - Read more

PulseSight Therapeutics' PST-611 shows positive Ph1 safety and efficacy signals in dry age-related macular degeneration
Gene therapy, neurological, non-viral gene therapy, age-related macular degeneration, geographic atrophy - Read more

Braveheart Bio and Hengrui Pharma's (BHB-1893) cardiac myosin inhibitor shows Ph2 promise in non-obstructive hypertrophic cardiomyopathy
Small molecule, cardiovascular, cardiac myosin inhibitor, hypertrophic cardiomyopathy, non-obstructive HCM - Read more

Delos Capital, AP Biosciences collaborate to incubate next-generation antibody-focused biotech companies
Co-development, antibody, autoimmune, venture building, R&D - Read more

Daiichi Sankyo targets $14.6B oncology sales by 2030, aiming for global top-five cancer company status
Antibody-drug conjugate, oncology, strategic, financial - Read more

Scarlet Therapeutics raises £3.2M ($4.35M) to advance engineered red blood cell therapies for metabolic diseases
Cell therapy, rare disease, metabolic disease, platform technology, preclinical - Read more

Algorithmiq raises €18M ($21.18M) in funding for quantum computing drug discovery expansion
Quantum computing, drug discovery, molecular simulation, software platform - Read more

Poolbeg Pharma secures Canadian patent for POLB 001 targeting cancer immunotherapy-induced cytokine release syndrome
Small molecule, oncology, intellectual property, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

CSL slashes revenue forecast by $600M, takes $5B impairment amid R&D failures and market erosion
Plasma-derived therapy, rare disease, financial, operational, strategic - Read more

Daiichi Sankyo takes $850M charge, scraps facility investment amid falling ADC demand forecast
Antibody-drug conjugate, oncology, financial, operational, cost reduction - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here